Table 2.
Adverse events reported by MS patients following the third dose of the COVID-19 vaccine.
| Study Population (n = 211) | |
|---|---|
| Any adverse events, n(%) | 115 (54.5%) |
| Fatigue | 50 (23.7%) |
| Pain at the injection site | 46 (21.8%) |
| Fever\chills, flu-like symptoms | 52 (24.6%) |
| Muscle or joint pain | 21 (10%) |
| Headache | 16 (7.6%) |
| Infection with SARS-CoV-2 after vaccination | 1 (0.5%) |
| New or worsening neurological symptomatology | 8 (3.8%) |
| GI symptoms | 8 (3.8%) |
| Dizziness | 4 (1.9%) |
| Infection with SARS-CoV-2 after vaccination | 1 (0.4%) |
| Faial tingling\paresthesia | 0 (0%) |
| Facial palsy | 0 (0%) |
| Acute MS Relapse, n(%)* | 7 (3.3%) |
| Time to relapse, days | |
| Median | 34 |
| Range | 14–67 |